| Aug 1 |
Adverum Biotechnologies Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted for Ixo-vec for the Treatment of Wet AMD
|
| Jul 19 |
More Than $10M Bet On Appian? Check Out These 3 Stocks Insiders Are Buying
|
| Jul 18 |
Is Adverum Biotechnologies Stock Outpacing Its Medical Peers This Year?
|
| Jul 17 |
26-Week Interim Analysis of the LUNA Phase 2 Trial Update Call
|
| Jul 17 |
Adverum Biotechnologies, Inc's (ADVM) 26-Week Interim Analysis of the LUNA Phase 2 Trial Update Transcript
|
| Jul 17 |
Adverum posts mid-stage data for wet AMD candidate
|
| Jul 17 |
Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting
|
| Jul 16 |
Wall Street Analysts Think Adverum Biotechnologies (ADVM) Could Surge 290.54%: Read This Before Placing a Bet
|
| Jul 10 |
Adverum Biotechnologies to Host Webcast to Review Clinical Data from the 26-Week Interim Analysis of the Ongoing LUNA Phase 2 Trial in Wet AMD Being Presented at ASRS Annual Meeting
|
| Jun 18 |
Adverum Biotechnologies to Participate in TD Cowen’s Genetic Medicines & RNA Summit
|
